CX3CL1 and atherosclerosis: Second, while fractalkine is present in atherosclerotic arteries and is involved in the development of atherosclerosis, we have not tested our fractalkine-targeted PA in an atherosclerotic model, and we may not observe similar localization as in the arterial injury model.